Row
C
CLYMAI Stock Diagnostic Report
Climb Bio slips after early-stage trial data for kidney disease drug
[OR] Climb Bio's stock price fell 6% following the Phase 1 trial data report for its IgA congenital disease treatment, CLYM116.
View Source Article ↗AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
CLYM Analysis History (Last 30 Days)